CDKN2A and lung carcinoma: Additionally, recent findings in lung cancer have found that RB1 and p16/CDKN2A are activated by trametinib, and have implicated RB status in sensitivity to MEK inhibitors in KRAS mutant lung cancer cells; however, the underlying processes responsible for this observation remain poorly understood28,29.